Sector News

Rebooted Merrimack names Sanofi Genzyme SVP as CEO

January 20, 2017
Life sciences

Merrimack Pharmaceuticals has lured Dr. Richard Peters from Sanofi Genzyme to serve as its CEO. Peters will take charge of a rebooted, slimmed-down organization that is focused on pushing three anticancer candidates through clinical proof of concept.

The appointment ends the search for a CEO that began when Robert Mulroy resigned in October. Since then, Gary Crocker has helmed the company, during which time it struck a deal with Ipsen to offload FDA-approved cancer drug Onivyde. That deal led Merrimack to further cut its staffing levels, resulting in the company Peters takes charge of looking very different from that left behind by Mulroy three months ago.

Responsibility for making a success of the plan will fall on Peters, a physician-scientist who spent the past nine years at Sanofi Genzyme. Peters joined Sanofi Genzyme as a medical affairs VP after spells at Onyx Pharmaceuticals and Amgen, and went on to rise to the post of head of global rare diseases.

That position gave Peters control of a $3 billion-a-year business with 10 commercial products. The new Merrimack, which is about to sell its one approved product, poses a different challenge.

Once the deal with Ipsen goes through, Merrimack will have $575 million more in cash, far fewer employees and no revenue generating products. That puts the focus on getting three experimental candidates to clinical proof of concept.

“With the support of the board of directors and the expected near-term infusion of capital, several compelling clinical assets are now primed to realize their full potential. Together with the rest of the management team, we plan on continuing to take substantial steps to grow our robust pipeline to its full potential, with an eye toward early data readouts,” Peters said in a statement.

The cash infusion from Ipsen is expected to see Merrimack through to the middle of 2019, by when the merits of the company’s decision to tie its fate to MM-121, MM-141 and MM-310 should be clearer.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”